Evaluating the Impact of Antibiotic Exposures as Time-Dependent Variables on the Acquisition of Carbapenem-Resistant Acinetobacter baumannii

Critical Care Medicine

Volumn 44, Issue 10, 2016, Pages e949-e956

  Munoz Price, L Silvia ^a   Rosa, Rossana ^b,c   Castro, Jose G ^c   Laowansiri, Panthipa ^d   Latibeaudiere, Rachel ^b   Namias, Nicholas ^c   Tarima, Sergey ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b JACKSON MEMORIAL HOSPITAL   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^d ORLANDO HEALTH   (United States)

Author keywords

Acinetobacter baumannii; carbapenem resistant; cohort; colonization; survival analysis; time dependent variable

Indexed keywords

AMINOGLYCOSIDE; ANTIBIOTIC AGENT; CARBAPENEM; CARBAPENEM DERIVATIVE; CEFAZOLIN; CEFEPIME; CEFOXITIN; CEFTRIAXONE; PIPERACILLIN PLUS TAZOBACTAM; QUINOLONE; SULTAMICILLIN; VANCOMYCIN; ANTIINFECTIVE AGENT;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTION; ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL COLONIZATION; BACTERIUM CULTURE; COHORT ANALYSIS; DISEASE SURVEILLANCE; DRUG EXPOSURE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TIME; ACINETOBACTER INFECTIONS; AGE; APACHE; COMORBIDITY; DRUG EFFECTS; FLORIDA; INTENSIVE CARE UNIT; MICROBIAL SENSITIVITY TEST; MIDDLE AGED; SEX DIFFERENCE; STATISTICS AND NUMERICAL DATA; TIME FACTOR;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ADULT; AGE FACTORS; ANTI-BACTERIAL AGENTS; APACHE; CARBAPENEMS; COMORBIDITY; DRUG RESISTANCE, BACTERIAL; FEMALE; FLORIDA; HUMANS; INTENSIVE CARE UNITS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; RETROSPECTIVE STUDIES; SEX FACTORS; TIME FACTORS;

EID: 84966710980     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0000000000001848     Document Type: Article

References (33)

1. Potron A, Poirel L, Nordmann P: Emerging broad-spectrum resistance in Pseudomonas aeruginosa and Acinetobacter baumannii: Mechanisms and epidemiology. Int J Antimicrob Agents 2015; 45: 568-585
2. Munoz-Price LS, Poirel L, Bonomo RA, et al: Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. Lancet Infect Dis 2013; 13: 785-796
3. Boucher HW, Talbot GH, Bradley JS, et al: Bad bugs, no drugs: No ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009; 48: 1-12
4. Boucher HW: Challenges in anti-infective development in the era of bad bugs, no drugs: A regulatory perspective using the example of bloodstream infection as an indication. Clin Infect Dis 2010; 50(Suppl 1): S4-S9
5. Spellberg B, Guidos R, Gilbert D, et al: Infectious Diseases Society of America: The epidemic of antibiotic-resistant infections: A call to action for the medical community from the Infectious Diseases Society of America. Clin Infect Dis 2008; 46: 155-164
6. Centers for Disease Control and Prevention: Antibiotic Resistance Threats in the United States, 2013. Available at: http: //www. cdc. gov/ drugresistance/threat-report-2013/. Accessed October 9, 2013
7. Buising KL, Thursky KA, Robertson MB, et al: Electronic antibiotic stewardship-reduced consumption of broad-spectrum antibiotics using a computerized antimicrobial approval system in a hospital setting. J Antimicrob Chemother 2008; 62: 608-616
8. Raymond DP, Pelletier SJ, Crabtree TD, et al: Impact of a rotating empiric antibiotic schedule on infectious mortality in an intensive care unit. Crit Care Med 2001; 29: 1101-1108
9. Cook PP, Catrou P, Gooch M, et al: Effect of reduction in ciprofloxacin use on prevalence of meticillin-resistant Staphylococcus aureus rates within individual units of a tertiary care hospital. J Hosp Infect 2006; 64: 348-351
10. Rahal JJ, Urban C, Horn D, et al: Class restriction of cephalosporin use to control total cephalosporin resistance in nosocomial Klebsiella. JAMA 1998; 280: 1233-1237
11. Bantar C, Sartori B, Vesco E, et al: A hospitalwide intervention program to optimize the quality of antibiotic use: Impact on prescribing practice, antibiotic consumption, cost savings, and bacterial resistance. Clin Infect Dis 2003; 37: 180-186
12. Carling P, Fung T, Killion A, et al: Favorable impact of a multidisciplinary antibiotic management program conducted during 7 years. Infect Control Hosp Epidemiol 2003; 24: 699-706
13. Amit S, Mishali H, Kotlovsky T, et al: Bloodstream infections among carriers of carbapenem-resistant Klebsiella pneumoniae: Etiology, incidence and predictors. Clin Microbiol Infect 2015; 21: 30-34
14. Nseir S, Blazejewski C, Lubret R, et al: Risk of acquiring multidrugresistant Gram-negative bacilli from prior room occupants in the intensive care unit. Clin Microbiol Infect 2011; 17: 1201-1208
15. Harris AD, McGregor JC, Johnson JA, et al: Risk factors for colonization with extended-spectrum beta-lactamase-producing bacteria and intensive care unit admission. Emerg Infect Dis 2007; 13: 1144-1149
16. Jongerden IP, Speelberg B, Satizábal CL, et al: The role of systemic antibiotics in acquiring respiratory tract colonization with gram-negative bacteria in intensive care patients: A nested cohort study. Crit Care Med 2015; 43: 774-780
17. Ong DS, Jongerden IP, Buiting AG, et al: Antibiotic exposure and resistance development in Pseudomonas aeruginosa and Enterobacter species in intensive care units. Crit Care Med 2011; 39: 2458-2463
18. Latibeaudiere R, Rosa R, Laowansiri P, et al: Surveillance cultures growing carbapenem-resistant Acinetobacter baumannii predict the development of clinical infections: A retrospective cohort study. Clin Infect Dis 2015; 60: 415-422
19. Munoz-Price LS, Carling P, Cleary T, et al: Control of a two-decade endemic situation with carbapenem-resistant Acinetobacter baumannii: Electronic dissemination of a bundle of interventions. Am J Infect Control 2014; 42: 466-471
20. Munoz-Price LS: Controlling multidrug-resistant Gram-negative bacilli in your hospital: A transformational journey. J Hosp Infect 2015; 89: 254-258
21. World Health Organization: ATC/DDD Index, 2015. Available at: http: //www. whocc. no/atc-ddd-index/. Accessed June 22, 2015
22. Allison PD: Survival Analysis Using SAS. Cary, NC, SAS Press, 2010
23. Sievert DM, Ricks P, Edwards JR, et al: National Healthcare Safety Network (NHSN) Team and Participating NHSN Facilities: Antimicrobial-resistant pathogens associated with healthcare-associated infections: Summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010. Infect Control Hosp Epidemiol 2013; 34: 1-14
24. Chitnis AS, Edwards JR, Ricks PM, et al: Device-associated infection rates, device utilization, and antimicrobial resistance in long-term acute care hospitals reporting to the National Healthcare Safety Network, 2010. Infect Control Hosp Epidemiol 2012; 33: 993-1000
25. Munoz-Price LS, Quinn JP: Deconstructing the infection control bundles for the containment of carbapenem-resistant Enterobacteriaceae. Curr Opin Infect Dis 2013; 26: 378-387
26. Centers for Disease Control and Prevention: Get Smart Program and Observances, 2014. Available at: http: //www. cdc. gov/getsmart/. Accessed June 22, 2015
27. Cisneros JM, Rodríguez-Baño J: Nosocomial bacteremia due to Acinetobacter baumannii: Epidemiology, clinical features and treatment. Clin Microbiol Infect 2002; 8: 687-693
28. Castelo Branco Fortaleza CM, Moreira de Freitas F, da Paz Lauterbach G: Colonization pressure and risk factors for acquisition of imipenem-resistant Acinetobacter baumannii in a medical surgical intensive care unit in Brazil. Am J Infect Control 2013; 41: 263-265
29. Lee SO, Kim NJ, Choi SH, et al: Risk factors for acquisition of imipenem-resistant Acinetobacter baumannii: A case-control study. Antimicrob Agents Chemother 2004; 48: 224-228
30. Ye JJ, Huang CT, Shie SS, et al: Multidrug resistant Acinetobacter baumannii: Risk factors for appearance of imipenem resistant strains on patients formerly with susceptible strains. PLoS One 2010; 5: e9947
31. Munoz-Price LS, Arheart K, Nordmann P, et al: Eighteen years of experience with Acinetobacter baumannii in a tertiary care hospital. Crit Care Med 2013; 41: 2733-2742
32. Schechner V, Straus-Robinson K, Schwartz D, et al: Evaluation of PCR-based testing for surveillance of KPC-producing carbapenemresistant members of the Enterobacteriaceae family. J Clin Microbiol 2009; 47: 3261-3265
33. Lowman W, Marais M, Ahmed K, et al: Routine active surveillance for carbapenemase-producing Enterobacteriaceae from rectal swabs: Diagnostic implications of multiplex polymerase chain reaction. J Hosp Infect 2014; 88: 66-71